Role of Oxidants and Antioxidants in Atherosclerosis: Results of In Vitro and In Vivo Investigations

Abstract

Both in vitro and in vivo studies have shown that oxidants are central in the development of atherosclerosis. Consequently, additional studies evaluated the protective effects of various natural and synthetic antioxidants, alone and in combination, with most studies focusing on α-tocopherol (vitamin E). Here, we summarize the role of oxidants in the pathomechanism of atherosclerosis. We also discuss epidemiological studies and others focused on the protective effect of vitamin E against atherosclerosis. Other antioxidants are also considered if they were included in studies involving vitamin E. The protective effect of antioxidants on atherosclerotic pathomechanisms has been confirmed in vitro, but only in some animal studies. Various epidemiological and observational studies have produced conflicting results on the protective effect of antioxidants. Most studies of primary or secondary prevention failed to show a protective effect. These conflicting results are biased by a number of factors, including differences between the study groups. Therefore, we describe these studies in detail.

Keywords

atherosclerosis cardiovascular disease oxidative stress antioxidants vitamin E vitamin C β-carotene

References

Yu BP Cellular defenses against damage from reactive oxygen species. Physiol Rev. 1994;74:139-162.

Ruef J. , Peter K. , Nordt TK , Runge MS , Kübler W. , Bode C. Oxidative stress and atherosclerosis: its relationship to growth factors, thrombus formation and therapeutic approaches. Thromb Haemost. 1999;82(suppl):32-37.

Locatelli F. , Canaud B. , Eckardt KU , Stenvinkel P. , Wanner C. , Zoccali C. Oxidative stress in end-stage renal disease: an emerging threat to patient outcome. Nephrol Dial Transplant. 2003;18:1272-1280.

Marfella R. , D'Amico M. , Esposito K. , et al. The ubiquitinproteasome system and inflammatory activity in diabetic atherosclerotic plaques. Diabetes. 2006;55:622-632.

Wright E. , Scim-Bacon JL , Glass LC Oxidative stress in type 2 diabetes: the role of fasting and postprandial glycaemia. Int J Clin Pract. 2003;60:308-314.

Zhang L. , Zalewski A. , Liu Y. , et al. Diabetes-induced oxidative stress and low-grade inflammation in porcine coronary arteries. Circulation. 2003;108:472-478.

Church DF , Pryor WA Free-radical chemistry of cigarette smoke and its toxicological implications . Environ Health Perspect. 1985;64:111-126.

Church DF , Pryor WA The oxidative stress placed on the lung by cigarette smoke. In: Crystal RG , West JB , eds. The Lung: Scientific Foundations. New York : Raven Press; 1991:1975-1980.

Pryor WA Oxy-radicals and related species: their formation, lifetimes and reactions . Annu Rev Physiol. 1986; 48:657-667.

10.

Pryor WA

How far does ozone penetrate into the pulmonary air/tissue boundary before it reacts?

Free Radic Biol Med. 1992 ;12:83-88.

11.

Niewoehner DE , Kleinermann J. , Rice DB Pathologic changes in the peripheral airways of young cigarette smokers. N Engl J Med. 1974;291:755-758.

12.

Halcox JPJ , Deanfield JE Beyond the laboratory: clinical implications for statin pleiotropy. Circulation. 2004; 109(Suppl II):II-42-II-48.

13.

Liao JK Clinical implications for statin pleiotropy. Curr Opin Lipidol . 2005;16:624-629.

14.

Ito MK , Talbert RL , Tsimikas S. Statin-associated pleiotropy: possible beneficial effects beyond cholesterol reduction. Pharmacotherapy. 2006;26:85S-97S.

15.

Stoll LL , McCormick ML , Denning GM , Weintraub NL

Antioxidant effects of statins. Timely Top Med

Cardiovasc Dis. 2005;9:E1.

16.

Pryor WA Vitamin E and heart disease: basic science to clinical intervention trials . Free Rad Biol Med. 2000;28: 141-164.

17.

Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 1993;362:801-809.

18.

Ross R. Atherosclerosis — An inflammatory disease. N Engl J Med. 1999;340:115-126.

19.

Steinberg D. , Parthasarathy S. , Carew TE , Khoo JC , Witztum JL Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity . N Engl J Med. 1989;320:915-924.

20.

Steinberg D. Lewis A. Conner memorial lecture: oxidative modification of LDL and atherogenesis. Circulation. 1997 ;95:1062-1071.

21.

Esterbauer H. , Jürgens G. Mechanistic and genetic aspects of susceptibility of LDL to oxidation. Curr Opin Lipidol. 1993 ;4:114-124.

22.

Stocker R. Lipoprotein oxidation: mechanistic aspects, methodological approaches and clinical relevance. Curr Opin Lipidol. 1994 ;5:422-433.

23.

Stocker R. , Keaney JF Role of oxidative modifications in atherosclerosis. Physiol Rev. 2004;84:1381-1478.

24.

Antoniades C. , Tousoulis D. , Tentolouris C. , Toutouzas P. , Stefanidis C. Oxidative stress, antioxidant vitamins, and atherosclerosis. From basic research to clinical practice. Herz. 2003;28:628-638.

25.

Biesalski HK , Esterbauer H. , Schmidt KH Vitamin E. In: Biesalski HK, Köhrle J, Schümann K, eds. Vitamine, Spurenelemente und Mineralstoffe. Prävention und Therapie mit Mikronährstoffen . Stuttgart : Georg Thieme-Verlag . 2002:14-20.

26.

Carr AC , Zhu BZ , Frei B. Potential antiatherogenic mechanisms of ascorbate (vitamin C) and α-tocopherol (vitamin E). Circ Res. 2000;87:349-354.

27.

Grune T. Antioxidanzien. In: Biesalski HK , Köhrle J , Schümann K , eds. Vitamine, Spurenelemente und Mineralstoffe. Prävention und Therapie mit Mikronährstoffen. Stuttgart: Georg Thieme-Verlag; 2002:50-56.

28.

Mason P. Vitamin C. In: Mason P , ed. Dietary Supplements. London: Pharmaceutical Press; 2001:227-233.

29.

Rota S. , McWilliam NA , Baglin TP , Byrne CD Atherogenic lipoproteins support assembly of the prothrombinase complex and thrombin generation: modulation by oxidation and vitamin E. Blood. 1998;91:508-515.

30.

Chan AC Vitamin E and atherosclerosis. J Nutr. 1998 ; 128:1593-1596.

31.

Colquhoun DM Nutraceuticals: vitamins and other nutrients in coronary heart disease. Curr Opin Lipidol. 2001;12:639-646.

32.

Ricciarelli R. , Zingg JM , Azzi A. Vitamin E: protective role of a Janus molecule . FASEB J. 2001;15:2314-2325.

33.

Drexler H. , Hornig B. Endothelial dysfunction in human disease. J Mol Cell Cardiol . 1999;31:51-60.

34.

Shimokawa H. Primary endothelial dysfunction: atherosclerosis . J Mol Cell Cardiol. 1999;31:23-37.

35.

Tousoulis D. , Antoniades C. , Stefanadis C. Nitric oxide in coronary artery disease: effects of antioxidants. Eur J Clin Pharmacol. 2006 ;62:101-107.

36.

Cai H. , Harrison DG Endothelial dysfunction in cardiovascular diseases. The role of oxidant stress . Circ Res. 2000;8:840-844.

37.

Landmesser U. , Hornig B. , Drexler H.

Endothelial function. A critical determinant in atherosclerosis?

Circulation. 2004;109(suppl II):II-27-II-33.

38.

Gryglewski RJ , Palmer RM , Moncada S. Superoxide anion is involved in the breakdown of endothelium-derived vascular relaxing factor . Nature. 1986;320: 454-456.

39.

Powell JT Vascular damage from smoking: disease mechanisms at the arterial wall . Vasc Med. 1998;3:21-28.

40.

Berliner JA , Navab M. , Fogelman AM , et al. Atherosclerosis: basic mechanisms. Oxidation, inflammation and genetics. Circulation . 1995;91:488-496.

41.

Egashira K. Clinical importance of endothelial function in arteriosclerosis and ischemic heart disease. Circ J. 2002;66:529-533.

42.

Tsuchiya M. , Asada A. , Kasahara E. , Sato EF , Shindo M. , Inoue N. Smoking a single cigarette rapidly reduces combined concentrations of nitrate and nitrite and concentrations of antioxidants in plasma. Circulation. 2002; 105:1155-1157.

43.

Devaraj S. , Jialal I. The effects of alpha-tocopherol on critical cells in atherogenesis . Curr Opin Lipidol. 1998;9:11-15.

44.

Brown AA , Hu FB Dietary modulation of endothelial function: implications for cardiovascular disease. Am J Clin Nutr. 2001;73:673-686.

45.

Su B. , Mitra S. , Gregg H. , et al. Redox regulation of vascular smooth muscle cell differentiation . Circ Res. 2001; 89:39-46.

46.

Heitzer T. , Just H. , Münzel T. Antioxidant vitamin C improves endothelial dysfunction in chronic smokers . Circulation. 1996;94:6-9.

47.

Nunes GL , Robinson K. , Kalynych A. , King SB , Sgoutas DS , Berk BC Vitamins C and E inhibit O2- production in the pig coronary artery. Circulation. 1977;96:3593-3601.

48.

Ricciarelli R. , Zingg JM , Azzi A. Vitamin E reduces the uptake of oxidized LDL by inhibiting CD36 scavenger receptor expression in cultured aortic smooth muscle cells. Circulation. 2000;102:82-87.

49.

Tasinato A. , Boscoboinik D. , Bartoli GM , Maroni P. , Azzi A. d-α-tocopherol inhibition of vascular smooth muscle cell proliferation occurs at physiological concentrations, correlates with protein kinase C inhibition, and is independent of its antioxidant properties . Proc Natl Acad Sci U S A. 1995;92:12190-12194.

50.

Freedman JE , Farhat JH , Loscalzo J. , Keaney JF αtocopherol inhibits aggregation of human platelets by a protein kinase C-dependent mechanism . Circulation . 1996;94:2434-2440.

51.

Dowd P. , Zheng ZB On the mechanism of the anticlotting action of vitamin E quinone. Proc Natl Acad Sci U S A. 1995;92:8171-8175.

52.

Devaraj S. , Li D. , Jialal I. The effects of alpha tocopherol supplementation on monocyte function. Decreased lipid oxidation, interleukin 1β secretion, and monocyte adhesion to endothelium . J Clin Invest. 1996;98:756-763.

53.

Islam KN , Devaraj S. , Jialal I. α-tocopherol enrichment of monocytes decreases agonist-induced adhesion to human endothelial cells. Circulation. 1998 ;98:2255-2261.

54.

Weber C. , Erl W. , Weber K. , Weber PC Increased adhesiveness of isolated monocytes to endothelium is prevented by vitamin C intake in smokers. Circulation. 1996;93:1488-1492.

55.

Devaraj S. , Hugou I. , Jialal I. Alpha-tocopherol decreases CD36 expression in human monocyte-derived macrophages . J Lipid Res. 2001;42:521-527.

56.

Abudu N. , Miller JJ , Attaelmannan M. , Levinson SS Vitamins in human arteriosclerosis with emphasis on vitamin C and vitamin E. Clin Chim Acta. 2004;339:11-25.

57.

Brigelius-Flohe R. , Traber MG Vitamin E: function and metabolism . FASEB J. 1999;13:1145-1155.

58.

Burton GW , Ingold KU Beta-carotene: an unusual type of lipid antioxidant. Science . 1984;224:569-573.

59.

Jessup W. Oxidized lipoproteins and nitric oxide. Curr Opin Lipidol . 1996;7:274-280.

60.

Kuhn H. , Chan L. The role of 15-lipoxygenase in atherogenesis: pro- and antiatherogenic actions . Curr Opin Lipidol. 1997;8:111-117.

61.

Patel RP , Levonen A. , Crawford JH , Darley-Usmar VM Mechanism of the pro- and anti-oxidant actions of nitric oxide in atherosclerosis . Cardiovasc Res. 2000;47:465-474.

62.

Podmore ID , Griffiths HR , Herbert KE , Mistry N. , Mistry P. , Lunec J. Vitamin C exhibits pro-oxidant properties. Nature . 1998;392:559.

63.

Young AJ , Lowe GM Antioxidant and prooxidant properties of carotenoids. Arch Biochem Biophys. 2001;385: 20-27.

64.

Munteanu A. , Zingg JM , Azzi A.

Anti-atherosclerotic effects of vitamin E — myth or reality?

J Cell Mol Med. 2004;8:59-76.

65.

Miller ER , Pastor-Barriuso R. , Dalal D. , Riemersma RA , Appel LJ , Guallar E. Meta-analysis: high-dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med. 2005;142:37-46.

66.

Fairfield KM , Fletcher RH Vitamins for chronic disease prevention in adults: scientific review. JAMA. 2002;287: 3116-3126.

67.

Mason P. Carotenoids. In: Mason P , ed. Dietary Supplements. London: Pharmaceutical Press; 2001:40-45.

68.

Stahl W. Carotinoide. In: Biesalski HK , Köhrle J , Schümann K , eds. Vitamine, Spurenelemente und Mineralstoffe. Prävention und Therapie mit Mikronährstoffen. Stuttgart: Georg Thieme-Verlag; 2002:41-49.

69.

Weber P. Vitamin C. In: Biesalski HK , Köhrle J , Schümann K , eds. Vitamine, Spurenelemente und Mineralstoffe. Prävention und Therapie mit Mikronährstoffen. Stuttgart: Georg Thieme-Verlag; 2002:57-69.

70.

Mason P. Vitamin E. In: Mason P , ed. Dietary Supplements. London: Pharmaceutical Press; 2001:240-247.

71.

Stocker R. Dietary and pharmacological antioxidants in atherosclerosis. Curr Opin Lipidol. 1999;10:589-597.

72.

Enstrom JE , Kanim LE , Klein MA Vitamin C intake and mortality among a sample of the United States population . Epidemiology. 1992;3:194-202.

73.

Gey KF , Stähelin HB , Eichholzer M. Poor plasma status of carotene and vitamin C is associated with higher mortality from ischemic heart disease and stroke: Basel Prospective Study . Clin Investig. 1993;71:3-6.

74.

Stampfer MJ , Hennekens CH , Manson JAE , Colditz GA , Rosner B. , Willett WC Vitamin E consumption and the risk of coronary disease in women. N Engl J Med. 1993;328:1444-1449.

75.

Rimm EB , Stampfer MJ , Ascherio A. , Giovannucci E. , Colditz GA , Willett WC Vitamin E consumption and the risk of coronary heart disease in men . N Engl J Med. 1993;328:1450-1456.

76.

Knekt P. , Reunanen A. , Järvinen R. , Seppänen R. , Heliövaara M. , Aromaa A. Antioxidant vitamin intake and coronary mortality in a longitudinal population study. Am J Epidemiol. 1994;139:1180-1189.

77.

Kritchevsky SB , Shimakawa T. , Tell GS , et al. Dietary antioxidants and carotid artery wall thickness. The ARIC study. Circulation . 1995;92:2142-2150.

78.

Losonczy KG , Harris TB , Havlik RJ Vitamin E and vitamin C supplement use and risk of all-cause and coronary heart disease mortality in older persons: the Established Populations for Epidemiologic Studies of the Elderly. Am J Clin Nutr. 1996;64:190-196.

79.

Kushi LH , Folsom AR , Prineas RJ , Mink PJ , Wu Y. , Bostick RM Dietary antioxidant vitamins and death from coronary heart disease in postmenopausal women. N Engl J Med. 1996 ;334:1156-1162.

80.

Yochum LA , Folsom AR , Kushi LH Intake of antioxidant vitamins and risk of death from stroke in postmenopausal women. Am J Clin Nutr. 2000;72: 476-483.

81.

Klipstein-Grobusch K. , Geleijnse JM , den Breeijen JH , et al. Dietary antioxidants and risk of myocardial infarction in the elderly: the Rotterdam Study. Am J Clin Nutr. 1999;69:261-266.

82.

Rissanen T. , Voutilainen S. , Nyyssönen K. , Salonen R. , Salonen JT Low plasma lycopene concentration is associated with increased intima-media thickness of the carotid artery wall. Arterioscler Thromb Vasc Biol. 2000; 20:2677-2681.

83.

Klipstein-Grobusch K. , den Breeijen JH , Grobbee DE , Boeing H. , Hofman A. , Witteman JCM. Dietary antioxidants and peripheral arterial disease. The Rotterdam Study. Am J Epidemiol. 2001;154:145-149.

84.

Hooper L. , Ness AR , Smith GD Antioxidant strategy for cardiovascular disease. Lancet. 2001;357:1704-1705.

85.

The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers . N Engl J Med. 1994;330:1029-1035.

86.

Rapola JM , Virtamo J. , Haukka JK , et al. Effect of vitamin E and beta carotene on the incidence of angina pectoris. A randomized, double-blind, controlled trial. JAMA. 1996;275:693-698.

87.

Omenn GS , Goodman GE , Thornquist MD , et al. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med. 1996;334:1150-1155.

88.

Hennekens CH , Buring JE , Manson JAE , et al. Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. N Engl J Med. 1996;334:1145-1149.

89.

Greenberg ER , Baron JA , Karagas MR , et al. Mortality associated with low plasma concentration of beta carotene and the effect of oral supplementation . JAMA. 1996;275:699-703.

90.

Salonen JT , Nyyssönen K. , Salonen R. , et al. Antioxidant supplementation in atherosclerosis prevention (ASAP) study: a randomized trial of the effect of vitamins E and C on 3-year progression of carotid atherosclerosis. J Intern Med. 2000;248:377-386.

91.

Collaborative Group of the Primary Prevention Project (PPP). Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Lancet. 2001;357:89-95.

92.

Hodis HN , Mack WJ , LaBree L. , et al, for the VEAPS Research Group. Alpha-tocopherol supplementation in healthy individuals reduces low-density lipoprotein oxidation but not atherosclerosis. The Vitamin E Atherosclerosis Prevention Study (VEAPS). Circulation. 2002 ;106:1453-1459.

93.

Törnwall ME , Virtamo J. , Korhonen PA , et al. Effect of α-tocopherol and β-carotene supplementation on coronary heart disease during the 6-year post-trial follow-up in the ATBC study. Eur Heart J. 2004;25:1171-1178.

94.

Salonen RM , Nyyssönen K. , Kaikkonen J. , et al. Six-year effect of combined vitamin C and E supplementation on atherosclerotic progression: the Antioxidant Supplementation in Atherosclerosis Prevention (ASAP) Study. Circulation. 2003 ;107:947-953.

95.

Hercberg S. , Preziosi P. , Briancon S. , et al. A primary prevention trial using nutritional doses of antioxidant vitamins and minerals in cardiovascular diseases and cancers in a general population: the SU.VI.MAX study-design, methods, and participant characteristics. Supplementation en VItamines et Mineraux Antio-Xydants . Control Clin Trials. 1998;19:336-351.

96.

Hercberg S. , Galan P. , Preziosi P. , et al. The SU.VI.MAX Study. A randomized, placebo-controlled trial of the health effects of antioxidant vitamins and minerals. Arch Intern Med. 2004 ;164:2335-2342.

97.

Christen WG , Gaziano JM , Hennekens CH Design of Physicians' Health Study II — a randomized trial of βcarotene, vitamins E and C, and multivitamins, in prevention of cancer, cardiovascular disease, and eye disease, and review of results of completed trials. Ann Epidemiol. 2000;10:125-134.

98.

Stephens NG , Parsons A. , Schofield PM , et al. Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS) . Lancet. 1996;347:781-786.

99.

Rapola JM , Virtamo J. , Ripatti S. , et al. Randomised trial of α-tocopherol and β-carotene supplements on incidence of major coronary events in men with previous myocardial infarction . Lancet. 1997;349:1715-1720.

100.

Tardif J.C. , Cote G. , Lesperance J. , et al, for the Multivitamins and Probucol Study Group. Probucol and multivitamins in the prevention of restenosis after coronary angioplasty. N Engl J Med. 1997;337:365-372.

101.

GISSI-Prevenzione Investigators (Gruppo Italiano per lo Studio della Sopravvivenza nell`Infarto miocardioc). Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Lancet. 1999; 354:447-455.

102.

The HOPE (Heart Outcomes Prevention Evaluation) Study: the design of a large, simple randomized trial of an angiotensin-converting enzyme inhibitor (ramipril) and vitamin E in patients at high risk of cardiovascular events. The HOPE study investigators. Can J Cardiol. 1996;12:127-137.

103.

The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000;342:145-153.

104.

The Heart Outcomes Prevention Evaluation Study Investigators. Vitamin E supplementation and cardiovascular events in high-risk patients. N Engl J Med. 2000;342:154-160.

105.

Boaz M. , Smetana S. , Weinstein T. , et al. Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial. Lancet. 2000;356:1213-1218.

106.

Brown BG , Zhao XQ , Chait A. , et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med. 2001;345:1583-1592.

107.

Lonn EM , Yusuf S. , Dzavik V. , et al, for the SECURE Investigators. Effects of ramipril and vitamin E on atherosclerosis. The study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE). Circulation . 2001;103:919-925.

108.

Fang JC , Kinlay S. , Beltrame J. , et al. Effect of vitamins C and E on progression of transplant-associated arteriosclerosis: a randomised trial. Lancet. 2002;359: 1108-1113.

109.

Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002; 360:7-22.

110.

Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002; 360:23-33.

111.

Waters DD , Alderman EL , Hsia J. , et al. Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women: a randomized controlled trial. JAMA. 2002;288:2432-2440.

112.

Bassuk SS , Albert CM , Cook NR , et al. The Women's Antioxidant Cardiovascular Study: design and baseline characteristics of participants. J Womens Health. 2004;13:99-117.

113.

Manson JE , Gaziano JM , Spelsberg A. , et al. A secondary prevention trial of antioxidant vitamins and cardiovascular disease in women. Rationale, design, and methods. The WACS Research Group . Ann Epidemiol. 1995;5:261-269.

114.

Manson JE , Bassuk SS , Stampfer MJ

Does vitamin E supplementation prevent cardiovascular events?

J Womens Health (Larchmt). 2003;12:123-136.

115.

The HOPE and HOPE-TOO Trial Investigators. Effects of long-term vitamin E supplementation on cardiovascular events and cancer. A randomized controlled trial. JAMA. 2005;293:1338-1347.

116.

Alkhenizan AH , Al-Omran MA The role of vitamin E in the prevention of coronary events and stroke. Meta-analysis of randomized controlled trials . Saudi Med J. 2004;25:1808-1814.

117.

Eidelman RS , Hollar D. , Hebert PR , Lamas GA , Hennekens CH Randomized trials of vitamin E in the treatment and prevention of cardiovascular disease. Arch Intern Med. 2004 ;164:1552-1556.

118.

Shekelle PG , Morton SC , Jungvig LK , et al. Effect of supplemental vitamin E for the prevention and treatment of cardiovascular disease. J Gen Intern Med. 2004;19:380-389.

119.

Vivekananthan DP , Penn MS , Sapp SK , Hsu A. , Topol EJ Use of antioxidant vitamins for the prevention of cardiovascular disease: meta-analysis of randomised trials. Lancet. 2003;361:2017-2023.

120.

Lonn E. , Shaikholeslami R. , Yi Q. , et al. Effects of ramipril on left ventricular mass and function in cardiovascular patients with controlled blood pressure and with preserved left ventricular ejection fraction: a sub-study of the Heart Outcomes Prevention Evaluation (HOPE) Trial. J Am Coll Cardiol. 2004;43:2200-2206.

121.

Christen WG , Buring JE , Manson JAE , Hennekens CH

Beta-carotene supplementation: a good thing, a bad thing, or nothing?

Curr Opin Lipidol. 1999;10:29-33.

122.

Devaraj S. , Jialal I. Antioxidants and vitamins to reduce cardiovascular disease. Curr Atheroscler Rep. 2000;2: 342-351.

123.

Krauss RM , Eckel RH , Howard B. , et al. AHA Dietary Guidelines: revision 2000: a statement for healthcare professionals from the nutrition committee of the American Heart Association . Circulation. 2000;102: 2284-2299.

124.

Pryor WA , Stahl W. , Rock CL Beta carotene: from biochemistry to clinical trials. Nutr Rev. 2000;58:39-53.

125.

Tribble DL , for the Nutrition Committee. Antioxidant consumption and risk of coronary heart disease: emphasis on vitamin C, vitamin E, and β-carotene. A statement for healthcare professionals from the American Heart Association. Circulation . 1999;99:591-595.

126.

Jialal I. , Traber M. , Devaraj S.

Is there a vitamin E paradox?

Curr Opin Lipidol. 2001;12:49-53.

127.

Violi F. , Micheletta F. , Iuliano L. Antioxidants and atherosclerosis. Eur Heart J Suppl. 2002;4(suppl B):B17-B21.

128.

Azzi A. , Breyer I. , Feher M. , et al. Specific cellular responses to α-tocopherol. J Nutr. 2000;130:1649-1652.

129.

Azzi A. , Breyer I. , Feher M. , et al. Nonantioxidant functions of α-tocopherol in smooth muscle cells. J Nutr. 2001;131:378S-381S.

130.

Duvall WL Endothelial dysfunction and antioxidants. Mt Sinai J Med. 2005;72:71-80.

131.

Jiang Q. , Christen S. , Shigenaga MK , Ames BN γ-tocopherol, the major form of vitamin E in the US diet, deserves more attention. Am J Clin Nutr. 2001;74: 714-722.

132.

Steinberg D. , Witztum JL

Is the oxidative modification hypothesis relevant to human atherosclerosis? Do the antioxidant trials conducted to date refute the hypothesis?

Circulation. 2002 ;105:2107-2111.

133.

Brigelius-Flohe R. , Kelly FJ , Salonen JT , Neuzil J. , Zingg JM , Azzi A. The European perspective on vitamin E: current knowledge and future research. Am J Clin Nutr. 2002;76:703-716.

134.

Kyaw M. , Yoshizumi M. , Tsuchiya K. , Izawa Y. , Kanematsu Y. , Tamaki T. Atheroprotective effects of antioxidants through inhibition of mitogen-activated protein kinases. Acta Pharmacol Sin. 2004;25:977-985.

135.

Huang HY , Appel LJ Supplementation of diets with αtocopherol reduces serum concentrations of γ- and δtocopherol in humans. J Nutr. 2003;133:3137-3140.

136.

Engler MM , Engler MB , Malloy MJ , et al. Antioxidant vitamins C and E improve endothelial function in children with hyperlipidemia: Endothelial Assessment of Risk from Lipids in Youth (EARLY) Trial. Circulation. 2003;108:1059-1063.

137.

Jessup W. , Kritharides L. , Stocker R. Lipid oxidation in atherogenesis: an overview. Biochem Soc Trans. 2004; 32:134-138.

138.

Upston JM , Kritharides L. , Stocker R. The role of vitamin E in atherosclerosis. Prog Lipid Res. 2003;42:405-422.

139.

Bjelakovic G. , Nikolova D. , Gluud LL , Simonetti RG , Gluud C. Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis . JAMA. 2007;297:842-857.